Does toxicity of cyclin-dependent kinase 4/6 inhibitor predict treatment response in metastatic hormone-positive breast cancer patients?
, 2, 3, 4, 5, 2, 6, 2, 2
Abstract
Introduction. In hormone receptor-positive metastatic breast cancer without human epidermal growth factor receptor 2 overexpression (HR+/HER2−), a significant progression-free survival benefit has been obtained with cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors in the first-line treatment. We mainly aimed to investigate whether the toxicities of CDK 4/6 inhibitors predict treatment response.
Material and methods. This study was designed retrospectively. A total of 191 patients diagnosed with metastatic HR+/HER2– breast cancer were treated with CDK 4/6 inhibitors in four centers in Türkiye included in our study.
Results. One hundred and six patients received ribociclib, and 85 patients received palbociclib. The most common adverse event in both groups was neutropenia. In this study, we found that toxicities did not predict response rates. Additionally, the response rates (RR) in patients with albumin levels above 4.1 g/dl were better than that in patients with albumin levels of 4.1 g/dl and below in multivariate analysis when all patients were considered (OR = 4.76; 95% CI 1.30–17.46; p = 0.018).
Conclusions. Toxicities of CDK4/6-inhibitors did not predict RRs. However, pretreatment albumin level may predict response to ribociclib.
Keywords: cyclin-dependent kinaseneutropeniametastatic breast cancerpalbociclibribociclib
References
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–249.
- Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016; 375(20): 1925–1936.
- Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016; 375(18): 1738–1748.
- Braal CL, Jongbloed EM, Wilting SM, et al. Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. Drugs. 2021; 81(3): 317–331.
- Sammons SL, Topping DL, Blackwell KL. HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles. Curr Cancer Drug Targets. 2017; 17(7): 637–649.
- Bono P, Rautiola J, Utriainen T, et al. Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. Acta Oncol. 2011; 50(4): 569–573.
- - NIH. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5. 0 Published: November : 2017.
- Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020; 382(6): 514–524.
- Turner NC, Slamon DJ, Ro J, et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2018; 379(20): 1926–1936.
- Onesti CE, Jerusalem G. CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. Expert Rev Anticancer Ther. 2021; 21(3): 283–298.
- Odan N, Kikawa Y, Matsumoto H, et al. Real-World Outcomes of Treating Advanced Breast Cancer Patients With Palbociclib: A Multicenter Retrospective Cohort Study in Japan-The KBCOG-14 Study. Breast Cancer (Auckl). 2020; 14: 1178223420983843.
- Sun J, Zhong X, Ma J, et al. Real-world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia. Cancer Med. 2021; 10(21): 7665–7672.